Nu-Med Plus, Inc. (OTCBB: NUMD), a medical device company which explores and develops medical applications of new technologies in the medical field, announced its patent filing for its new portable rapid distribution Nitric Oxide generating technology.

Nitric oxide is a medically essential gas that is presently used in Neonate Hypoxia therapy. Contemporary research is being done for additional applications involving the therapeutic need for vasodilation and increased delivery of oxygen to diseased and injured tissues. Nu-Med Plus has developed a unique concept for the generation of Nitric Oxide that has the capability to rapidly deliver the gas when serious and instantaneous use is needed. A patent has been applied for protecting this innovative advancement. "Nu-Med's goal is to expand its intellectual property portfolio by developing exceptional products like our portable rapid distribution technology which should enable us to add value to the company and increases our competitive advantage," commented Mr. Jeff Robins, President/CEO of Nu-Med Plus.

About Nu-Med Plus, Inc.

Nu-Med Plus, Inc. is a medical device development company created to explore medical applications of newly technologies. The strategy is to focus on potential markets where there is a clearly defined need recognized by the medical community that can be addressed by Nu-Med Plus and its technical expertise. Initial research and product development has been in the delivery of inhaled nitric oxide gas for therapeutic use. For more information please visit www.nu-medplus.com.

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's ability to complete proposed private placement financing. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.